Influential patients are reaching critical mass. What can't they do?
Medibid users auction up care in exchange for a low price.
Health insurer WellPoint found patients chose lower-priced MRIs when shown how much locations charged for the very same procedure, but the motivation is murky.
Patients want to do more with mobile and see doctors less. Two studies outline the types of digital interventions patients are interested in.
Credit card and loyalty program purchases will help Carolinas HealthCare System flag potential patient behavior issues.
The drugmaker's outreach efforts involve switching patients to the latest—and patented—Copaxone formulation.
A study showed that side-effect fears keep asthmatics from sticking to medication regimens.
The publisher aims to bring patient stories to life through long-form multimedia narratives.
Smartphone users, while in the exam room, are more apt to be in "switch mentality," a study finds.
The short answer: we're not financially prepared for a slowly aging, healthy population, according to a recently published analysis.
A study shows consumers are increasingly pleased with retail pharmacies, compared to mail order pharmacies, which are often considered a key means of driving adherence and lowering healthcare coverage costs.
The first on-demand way to tap the influencer community in healthcare went live today, and results of a real-world test show it has the potential to accelerate the research process.
The partnership seeks to improve medication adherence through predictive analytics.
AbbVie and Galapagos go after cystic fibrosis; FDA's NME approval pace slows; government shutdown could slow ad-com votes; and a report shows privately insured patients had emptier pockets in 2012 than 2011
An upcoming leadership summit is devoted to exploring whether health social media is driving meaningful change, as well as new ways to engage with health activists.
Researchers say using additional data points offers greater insight into patient-adherence patterns.
For women suffering from breast cancer, online tools appeared to be helpful in battling depression, a randomized trial showed.
Re-Mission, the video simulation known to change young patients' attitudes toward cancer, is in its second iteration. And one big drug maker has added its backing.
Sales may be rising, but a new study finds current psoriasis therapies leave room for improvement. Over half of patients said they want better options.
The state's first patient portal has officially entered development, and the e-health firm leading the effort said that a former WebMD executive joined its board.
Patient use of the professional app prompted the latest iteration, and the foundation behind it is set to launch a media push.
Companies are moving toward more access to clinical trial data. Despite their new stance, the internal battles haven't quite ended, some say.
China's industry investigation widens beyond GlaxoSmithKline; PhRMA's European equivalent rallies patient groups to fight transparency; Biogen Idec says a patient's death is not linked to Tecfidera; parents swap walk-in clinics for office visit; Roche continues its CEO hunt; and Forest logs 6% sales growth.
A study highlights medical service trends among patients with high-deductible plans but lacks insight on health impact and long-term costs.
JAMA's look into the impact of patient centric care shows that a broader scope is needed to understand the financial and health impact of active patients and how doctors perceive what it means to be engaged with patients.
The new survey will study whether patients understand how efficacy is calculated and experiment with ways to make communications clearer.
Two studies released show that the story behind lower consumer healthspend isn't about generics improving health.
The CEO's unexpected departure is part of the health information brand's latest changes. On the table: possible acquisitions. In progress: a new federal contract and new website content. Ignored: if the company wants to be bought.
A new FDA site gives patients a one-stop shop for commenting on pending regulations, finding clinical trials and navigating treatment options.
The FDA wants to know how physician attitudes towards direct-to-consumer advertising have evolved since the agency last asked them, in 2002. If a snap poll by CMI/Compas is any indication, drug companies probably won't like the answers.